Prophylactic Misoprostol-Oxytocin Combination in Preventing Postpartum Hemorrhage : A Meta-Analysis
DOI:
https://doi.org/10.25077/aoj.9.2.167-177.2025Keywords:
Postpartum Hemorrhage (PPH), Misoprostol, OxytocinAbstract
Background: Postpartum hemorrhage (PPH) remains the leading cause of maternal mortality worldwide. Active management of the third stage of labor, including prophylactic uterotonics, is essential in reducing PPH incidence. Oxytocin is the first-line agent; however, misoprostol has been considered as an adjunct due to its stability, accessibility, and effectiveness. This meta-analysis evaluates the efficacy of the misoprostol-oxytocin combination compared to oxytocin alone in preventing PPH.
Methods: A systematic literature search was conducted following PRISMA guidelines using PubMed, ScienceDirect, and Cochrane Library up to November 28, 2024. Randomized controlled trials (RCTs) comparing the misoprostol-oxytocin combination versus oxytocin alone for PPH prevention were included. Statistical analysis was performed using Review Manager 5.4, with mean difference (MD) and relative risk (RR) as effect measures. Heterogeneity was assessed using the I² statistic.
Results: A total of seven RCTs met the inclusion criteria. The misoprostol-oxytocin combination significantly reduced the risk of PPH compared to oxytocin alone (RR 0.71; 95% CI 0.55–0.91; p=0.007; I²=54%). Blood loss was significantly lower in the combination group (MD -33.77 mL; 95% CI -62.27 to -5.26; p=0.02; I²=80%). Hemoglobin drop was also reduced (MD -0.75 g/dL; 95% CI -1.48 to -0.01; p=0.02; I²=84%). However, the combination therapy was associated with a higher incidence of pyrexia.
Conclusion:The combination of misoprostol and oxytocin is more effective than oxytocin alone in reducing postpartum blood loss and hemoglobin drop. Despite increased pyrexia rates, its benefits in preventing PPH may outweigh the risks, particularly in high-risk populations. Further large-scale studies are needed to refine dosing strategies and assess long-term outcomes.
References
2. T. Amanuel, A. Dache and A. Dona, "Postpartum Hemorrhage and its Associated Factors Among Women who Gave Birth at Yirgalem General Hospital, Sidama Regional State, Ethiopia," Health Service Research and Managerial Epidemiology, vol. 8, 2021.
3. S. Jabeen, A. B. Siddique, A. T. Hossain, S. Khan and M. M. Haider, "Haemorrhage-related maternal mortality in Bangladesh: Levels, trends, time of death, and care-seeking practices based on nationally representative population-based surveys," Journal of Global Health, vol. 13, p. 07001, 2023.
4. L. Sentilhes, C. Vayssiere, C. Deneux-Tharaux, A. G. Aya, F. Bayoumeu and M.-P. Bonnet, "Postpartum hemorrhage: guidelines for clinical practice from the French College of Gynaecologists and Obstetricians (CNGOF): in collaboration with the French Society of Anesthesiology and Intensive Care (SFAR)," European Journal of Gynecology and Reproductive Biology, vol. 198, pp. 12-21, 2016.
5. O. Tuncalp, J. P. Souza and M. Gulmezoglu, "New WHO recommendations on prevention and treatment of postpartum hemorrhage," International Journal of Gynecology and Obstetric, vol. 123, no. 3, pp. 254-256, 2013.
6. M. K. Roach, A. Abramovici and A. T. N. Tita, "Dose and duration of oxytocin to prevent postpartum hemorrhage: a review," American Journal of Perinatology, vol. 30, no. 7, pp. 523-528, 2013.
7. L. C. Phung, E. K. Farrington, M. Connolly and A. N. Wilson, "Intravenous oxytocin dosing regimens for postpartum hemorrhage prevention following cesarean delivery: a systematic review and meta-analysis," American Journal of Obstetrics and Gynecology, vol. 225, no. 3, 2021.
8. J. L. Doyle, T. H. Kenny, M. D. Gothard, E. Seagraves, m. McCarroll and A. Silber, "A Standardized Oxytocin Administration Protocol After Delivery to Reduce the Treatment of Postpartum Hemorrhage," Jt Comm J Qual Patient Saf , vol. 45, no. 2, pp. 131-143, 2019.
9. C. M. Begley, G. M. L. Gyte, D. Devane, W. McGuire and A. Weeks, "Active versus expectant management for women in the third stage of labour," Cochrane Database of Systematic Review, vol. 9, no. 11, 2011.
10. A. R. Hersh, G. Carroli, G. J. Hofmeyr and B. Garg, "Third stage of labor: evidence-based practice for prevention of adverse maternal and neonatal outcomes," American Journal of Obstetrics and Gynecology, vol. 230, no. 3, pp. 1046-1060, 2024.
11. B. Fissahaye, A. N. Dheresa, A. Eyeberu, B. Balis and A. Debella, "Active management of the third stage of labor and associated factors among maternity care providers in public health facilities in Eastern Ethiopia: a multi-center study," BMC Pregnancy and Childbirth, vol. 23, p. 701, 2023.
12. G. Westhoff, A. M. Cotter and J. E. Tolosa, "Prophylactic oxytocin for the third stage of labour to prevent postpartum haemorrhage," Cochrane Database Systematic Review, vol. 30, no. 10, p. 1808, 2013.
13. J. A. Salati, S. J. Leathersich, M. J. Williams, A. Cuthbert and J. E. Tolosa, "Prophylactic oxytocin for the third stage of labour to prevent postpartum haemorrhage," Cochrane Database of Systematic Reviews, vol. 2019, no. 4, 2019.
14. S. J. McDonald, "Prophylactic ergometrine‐oxytocin versus oxytocin for the third stage of labour," Cochrane Database of Systematic Review, vol. 2004, no. 1, 2004.
15. A. Garrigue and F. Pierre, "Misoprostol: off-label use in the treatment of post-partum hemorrhage," Journal of Gynecology, Obstetrics and Biological Reproduction, vol. 43, no. 2, pp. 179-189, 2014.
16. H. Marret, E. Simon, G. Beucher, M. Dreyfus, A. Gaudineau, C. Vayssiere, M. Lesavre and M. Pluchon, "Overview and expert assessment of off-label use of misoprostol in obstetrics and gynaecology: review and report by the Collège national des gynécologues obstétriciens français," European Journal of Obstetrics and Gynecology, vol. 187, no. 80-94, 2015.
17. N. M. Alharthi, M. S. Alsaeed, M. O. Alsharif, M. G. Almalki and W. S. Alshehri, "Retrospective Study on the Pattern of Off-label Use of Misoprostol in Tabuk, Saudi Arabia," Journal of Pharmacy and BioAllied Science, vol. 13, no. 1, pp. 88-92, 2020.
18. R. J. Derman, B. S. Kodkany, S. S. Goudar, S. E. Geller, V. Naik, M. B. Bellad, S. S. Patted, A. Patel and S. A. Edlavitch, "Oral misoprostol in preventing postpartum haemorrhage in resource-poor communities: a randomised controlled trial," Lancet, vol. 368, no. 9543, pp. 1248-1253, 2006.
19. A. Kent, "Off-Label Use of Misoprostol and Oxytocin," Reviews in Obstetrics and Gynecology, vol. 2, no. 4, pp. 245-246, 2009.
20. Z. Alfirevic, J. Blum, G. Walraven, A. Weeks and B. Winikoff, "Prevention of postpartum hemorrhage with misoprostol," International Journal of Gynecology and Obstetrics, vol. 99, no. 2, pp. 198-201, 2007.
21. N. Prata and K. Weidert, "Efficacy of misoprostol for the treatment of postpartum hemorrhage: current knowledge and implications for health care planning," International Journal of Women's Health, vol. 8, pp. 341-349, 2016.
22. Y. S. Chong, S. Chua, H. El-Refaey, W. L. Choo, B. Chanrachakul, B. C. Tai, C. Rodeck and S. Arulkumaran, "Postpartum intrauterine pressure studies of the uterotonic effect of oral misoprostol and intramuscular syntometrine," BJOG, vol. 108, no. 1, pp. 41-47, 2001.
23. O. Tuncalp, G. J. Hofmeyr and A. M. Gulmezoglu, "Prostaglandins for preventing postpartum haemorrhage," Cochrane Database of Systematic Review, vol. 2012, no. 8, 2012.
24. Y. Chen, W. Jiang, Y. Zhao, D. Sun, X. Zhang and F. Wu, "Prostaglandins for Postpartum Hemorrhage: Pharmacology, Application, and Current Opinion," Pharmacology, vol. 106, no. 9-10, pp. 477-487, 2021.
25. T. Quibel, I. Ghout, F. Goffinet, L. J. Salomon, J. Fort, S. Javoise and L. Bussieres, "Active Management of the Third Stage of Labor With a Combination of Oxytocin and Misoprostol to Prevent Postpartum Hemorrhage: A Randomized Controlled Trial," Obstetrics and Gynecology, vol. 128, no. 4, pp. 805-11, 2016.
26. A. M. Gulmezoglu, J. Villar, N. T. Ngoc, G. Piaggio, G. Carroli, L. Adetoro, H. Abdel-Aleem, L. Cheng, G. Hofmeyr and G. Lumbiganon, "WHO multicentre randomised trial of misoprostol in the management of the third stage of labour," Lancet, vol. 358, no. 9283, pp. 689-695, 2001.
27. E. Caliskan, B. Dilbaz, M. M. Meydanli, N. Ozturk, M. A. Narin and A. Haberal, "Oral misoprostol for the third stage of labor: a randomized controlled trial," Obstetric and Gynecology, vol. 101, no. 5, pp. 921-928, 2003.
28. G. Westhoff, A. M. Cotter and J. E. Tolosa, "Prophylactic oxytocin for the third stage of labour to prevent postpartum haemorrhage," Cochrane Database of Systematic Review, vol. 30, no. 10, 2013.
29. A. J. Butwick, B. Carvalho, Y. J. Blumenfield, Y. Y. El-Sayed and L. M. Nelson, "Second Line Uterotonics and The Risk of Hemorrhage-Related Morbidity," American Journal of Obstetrics and Gynecology, vol. 212, no. 5, p. 642, 2015.
30. N. M. Cole, J. J. Kim, M. I. Marquez, K. G. Fields, L. M. Pino and M. K. Farber, "Second-Line Uterotonics for Uterine Atony: A Randomized Controlled Trial," Obstetrics and Gynecology, vol. 144, no. 6, pp. 832-8421, 2024.
31. M. F. Escobar, A. H. Nassar, G. Theron, E. R. Barnea and W. Nicholson, "FIGO recommendations on the management of postpartum hemorrhage 2022," International Journal of Gynecology and Obstetrics, vol. 157, no. S1, 2022.
32. A. J. Jones, J. J. Federspiel and A. C. Eke, "Preventing postpartum hemorrhage with combined therapy rather than oxytocin alone," American Journal of Obstetrics and Gynecology, vol. 5, no. 2S, p. 100371, 2023.
33. I. D. Gallos, A. Papadopoulou, R. Man, N. Athanasopoulos and A. Tobias, "Uterotonic agents for preventing postpartum haemorrhage: a network meta‐analysis," Cochrane Database of Systematic Review, vol. 2018, no. 12, p. 11689, 2018.
34. H. Pakniat and M. B. Khezri, "The Effect of Combined Oxytocin–Misoprostol Versus Oxytocin and Misoprostol Alone in Reducing Blood Loss at Cesarean Delivery: A Prospective Randomized Double-Blind Study," Journal of Obstetrics and Gynecology of India, vol. 65, no. 6, pp. 376-381, 2015.
35. T. A. Ottun, A. A. Adewunmi, A. K. Rabiu and A. Olumodeji, "Misoprostol and oxytocin versus oxytocin alone in the active management of the third stage of labour: a randomised, double-blind, placebo-controlled trial," Journal of Obstetrics and Gynecology, vol. 42, no. 5, pp. 1048-1053, 2022.
36. C. Cetin, H. R. Dural, P. Ozcan and F. B. Tanoglu, "The efficacy of three regimes of uterotonic agents for prevention of postpartum blood loss at undergoing cesarean section: a prospective randomized clinical trial," Via Medica, vol. 94, no. 9, pp. 751-757, 2023.
37. Y. s. Chong, S. Chua, H. El-Refaey, W. L. Choo, B. Chanrachakul, B. C. Tai and S. Arulkumaran, "Postpartum intrauterine pressure studies of the uterotonic effect of oral misoprostol and intramuscular syntometrine," BJOG, vol. 108, no. 1, pp. 41-47, 2001.
38. Y. s. Chong, S. Chua and S. Arulkumaran, "Severe hyperthermia following oral misoprostol in the immediate postpartum period," Obstetrics and Gynecology, vol. 90, no. 4, pp. 703-704, 1997.
39. P. N. Tolefac and J. Z. Minkande, "Sublingual misoprostol and hyperpyrexia: case report with temperature curve," BMC Research Notes, vol. 10, p. 329, 2017.
40. Z. Bilgin and N. Komurcu, "Comparison of the effects and side effects of misoprostol and oxytocin in the postpartum period: A systematic review," Taiwan Journal of Obstetric and Gynecology, vol. 58, no. 6, pp. 748-756, 2019.
41. J. Durocher, J. Bynum, W. Leon, G. Barrera and B. Winikoff, "High fever following postpartum administration of sublingual misoprostol," BJOG, vol. 117, no. 7, pp. 845-852, 2010.
42. W. Sringamwong, S. Saokaew and P. Mongkhon, "Optimal dose of misoprostol combined with oxytocin for preventing postpartum hemorrhage in cesarean section: A randomised controlled trial," Annals of Medicine and Surgery, vol. 78, no. 103931, 2022.
43. L. C. A. Esba, G. A. Mardawi and E. Al Mardawi, "Misoprostol-Induced Fever and Unnecessary Antibiotic Prescribing: A Retrospective Study," Infectious Disease and Therapy, vol. 12, no. 9, pp. 2259-2268, 2023.
44. J. Durocher, J. D. Aguirre, I. G. Dzuba, E. M. Morales and G. Carroli, "High fever after sublingual administration of misoprostol for treatment of post‐partum haemorrhage: a hospital‐based, prospective observational study in Argentina," Tropical Medicine and International Health, vol. 25, no. 6, pp. 714-722, 2020.
45. N. F. Zuberi, J. Durocher, R. Sikander, N. Baber, J. Blum and G. Walraven, "Misoprostol in addition to routine treatment of postpartum hemorrhage: A hospital-based randomized-controlled trial in Karachi, Pakistan," BMC Pregnancy and Childbirth, vol. 8, no. 40, 2008.
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2025 Gilang Rizqy Perdana Aries Rohman, Lani Diana, Tatik Sujiati

This work is licensed under a Creative Commons Attribution 4.0 International License.





